Benzydamine, chlorhexidine gluconate (Chlorzyd Antiseptic Throat Gargle, Chlorzyd Anttiseptic Throat)
Benzydamine, chlorhexidine gluconate
Unicorn Pharmaceuticals (Pty) Ltd
Registration
- Applicant
- Unicorn Pharmaceuticals (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Chlorzyd antiseptic throat gargle EACH 15,0 ml SOLUTION CONTAINS BENZYDAMINE HYDROCHLORIDE 22,0 mg CHLORHEXIDINE GLUCONATE 18,0 mg | Not listed | 53060653/16.4/0606 | Registered | Not determined | None |
| Chlorzyd anttiseptic throat spray EACH 30,0 ml SOLUTION CONTAINS BENZYDAMINE HYDROCHLORIDE 45,0 mg CHLORHEXIDINE GLUCONATE 36,0 mg | Spray | 53060753/16.4/0607 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Benzydamine
- except preparations and mixtures-
- containing 3 percent or less of benzydamine, when intended for application to the skin; (S0)
- containing more than 3 percent of benzydamine, but not exceeding 5 percent, when intended for application to the skin; (S1)
- intended for use as a mouth rinse or for topical application in the mouth and throat; provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day; (S1)
- containing 3 milligrams or less of benzydamine per throat lozenge: Provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day and the pack size does not exceed 16 lozenges. (S0)
- intended for human vaginal use. (S2)
Consolidated Schedules 06 July 2026, lines 3189 to 3203
S2: Benzydamine
- when intended for human vaginal use; (S3)
- except preparations and mixtures containing 3 percent or less of benzydamine, when intended for application to the skin; (S0)
- except preparations containing more than 3 percent of benzydamine, but not exceeding 5 percent, when intended for application to the skin; (S1)
- except preparations and mixtures intended for use as a mouth rinse or for topical application in the mouth and throat; provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day; (S1)
- except preparations and mixtures containing 3 milligrams or less of benzydamine per throat lozenge: Provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day and the pack size does not exceed 16 lozenges. (S0)
Consolidated Schedules 06 July 2026, lines 1660 to 1676
S1: Benzydamine
- preparations and mixtures intended for use as a mouth rinse or for topical application in the mouth and throat; provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day. (S3)
- preparations containing more than 3 percent of benzydamine, but not exceeding 5 percent, when intended for application to the skin; (S3)
- except preparations and mixtures containing 3 percent or less of benzydamine, when intended for application to the skin; (S0) or
- except preparations and mixtures containing 3 milligrams or less of benzydamine per throat lozenge: Provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day and the pack size does not exceed 16 lozenges; (S0)
- except when indicated for human vaginal use. (S2)
Consolidated Schedules 06 July 2026, lines 172 to 188
S1: Chlorhexidine
- when intended for human vaginal use.
Consolidated Schedules 06 July 2026, line 320
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.